DRTE Dendrite International (MM)

Executives from Dendrite International, Inc. (NASDAQ: DRTE) will be speaking at the Bear Stearns 19th Annual Healthcare Conference, which will be held September 11-12, 2006, at the Grand Hyatt in New York City. The conference will feature presentations by companies covering all sectors of the healthcare industry. On Monday, September 11, 2006 at 11:30 am ET (Eastern Time), John Bailye, Chairman and CEO and Jeffrey Bairstow, EVP and CFO will discuss Dendrite's business and future growth opportunities. A link to a live and replayed webcast will be available at www.dendrite.com in the Investors Highlights section. About Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com. For more information on OPUS Health, please visit www.opushealth.com. Note: Dendrite is a registered trademark of Dendrite International, Inc. This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers, including the risk associated with one substantial customer currently assessing its U.S. sales force effectiveness services needs; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations and our ability to adapt and respond successfully to other unique risks involved in our non-U.S. operations; integrating the entities we acquire; and our ability to effectively manage our growth. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements and the information provided in this press release should not be construed as updating, modifying or confirming the company's most recent financial outlook or guidance.